Fuling Technology
001356
KLT
831689
Hand Enterprise Solutions
300170
4
Kinco Automation (Shanghai) Co.,Ltd
688160
5
Doushen(Beijing) Education & Technology Inc.
300010
US Stock MarketDetailed Quotes
JAZZ Jazz Pharmaceuticals
- 120.840
- -0.590-0.49%
Close Jan 22 16:00 ET
- 120.840
- 0.0000.00%
Post 16:31 ET
7.31BMarket Cap17.12P/E (TTM)
122.290High120.335Low313.90KVolume121.550Open121.430Pre Close38.06MTurnover0.54%Turnover Ratio19.81P/E (Static)60.45MShares134.17052wk High1.75P/B7.09BFloat Cap99.06052wk Low--Dividend TTM58.67MShs Float194.730Historical High--Div YieldTTM1.61%Amplitude0.515Historical Low121.235Avg Price1Lot Size
About Jazz Pharmaceuticals Company
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Company Profile
SymbolJAZZ
Company NameJazz Pharmaceuticals
Listing DateJun 1, 2007
Issue Price18.00
Founded2005
CEOMr. Bruce C. Cozadd
MarketNASDAQ
Employees2800
Fiscal Year Ends12-31
AddressWaterloo Exchange,Waterloo Road,5th Floor
CityDublin
ProvinceDublin
CountryIreland
Zip Code4
Phone353-1-634-7800
Company Executives
- Name
- Position
- Salary
- Bruce C. Cozadd
- Chairman of the Board and Chief Executive Officer
- 15.34M
- Philip L. Johnson
- Executive Vice President and Chief Financial Officer
- --
- Renee D. Gala
- President and Chief Operating Officer
- 5.43M
- Patricia Carr
- Senior Vice President and Chief Accounting Officer
- 1.40M
- Neena M. Patil
- Executive Vice President and Chief Legal Officer
- 3.88M
- Samantha Pearce
- Senior Vice President, Europe and International
- --
- Dr. Robert Iannone, M.D.
- Executive Vice President and Global Head of Research and Development
- 4.98M
- Liz Henderson
- Senior Vice President, Technical Operations
- --
- Anne O'Riordan
- Independent Director
- 523.77K
- Patrick G. Enright, M.B.A.
- Independent Director
- 526.27K
- Kenneth W. O'Keefe
- Independent Director
- 513.77K
- Dr. Norbert G. Riedel,PhD
- Independent Director
- 533.77K
- Dr. Mark D. Smith, M.D.
- Independent Director
- 521.27K
- Heather Ann McSharry
- Independent Director
- 543.77K
- Seamus C. Mulligan
- Independent Director
- 531.27K
- Laura J. Hamill
- Independent Director
- --
- Patrick Thomas Kennedy
- Independent Director
- --
- Jennifer E. Cook
- Independent Director
- 533.77K
- Rick E. Winningham
- Lead Independent Director
- 571.27K
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
December CPI comes in as expected, is that enough?
U.S. December CPI rose 2.9% year-on-year, aligning with expectations but marking a three-month inflation increase trend. The market reacted
In One Chart
Jan 15 22:05
Here's the Breakdown for December CPI, in One Chart